Investing in synthetic biology: Rewriting life’s code
The field promises to redefine the future of food and materials, but it also presents a host of ethical dilemmas, regulatory hurdles, and risks of unforeseen consequences that investors must carefully consider
AS SYNTHETIC biology rapidly advances, transforming agriculture and materials science, investors are increasingly captivated by the possibility of rewriting life at its very core. This groundbreaking field promises extraordinary breakthroughs, but it also compels us to confront some of the most profound questions about ethics, regulation, and the unforeseen risks that come with manipulating the genetic code of organisms.
In a world stifled by climate anxiety, dwindling resources, and the urgency for sustainability, synthetic biology emerges as a potential solution – one that seeks to redesign organisms to meet humanity’s most pressing needs. Whether it’s lab-grown meats or bioengineered materials, the scope of this field reaches far beyond traditional scientific innovation – it has the power to radically reshape industries, economies, and even social norms. But is society ready for this transformation?
Having evolved from niche science to a Wall Street phenomenon, synthetic biology is now attracting major investment. Companies are pioneering genetic modifications that promise to revolutionise sectors like agriculture, with crops engineered to consume less water, and materials designed to replace petroleum-based products with bio-fabricated alternatives. The global synthetic biology market, valued at US$10 billion in 2021, is projected to skyrocket to US$38.7 billion by 2027, far outpacing traditional industries. Yet, behind these ambitious projections lies a tangle of complexities and uncertainties that investors must navigate carefully.
Synthetic biology in the food industry
Perhaps the most celebrated – and controversial – application of synthetic biology lies in the food industry. Lab-grown meats and dairy, once the stuff of dystopian fiction, are now being presented as sustainable, ethical alternatives to traditional livestock farming. Companies like Memphis Meats and Perfect Day are leading the charge, aiming to disrupt the US$1.4 trillion global meat market by offering “guilt-free” consumption. But while the vision is compelling, the journey toward widespread market adoption is far from smooth.
In 2020, over US$3.1 billion was invested in alternative protein ventures, drawn by the promise of feeding the world without the environmental cost. But this vision raises significant questions. Regulatory bodies struggle to define and regulate these novel products, and the path to achieving cost parity with conventional meat remains elusive. Furthermore, consumer acceptance remains unpredictable – deep-seated cultural and psychological barriers may prove far more resistant than anticipated.
Revolutionising materials science
Synthetic biology’s potential extends beyond food into materials science. Companies are now engineering microorganisms to produce bio-based materials such as spider silk and faux leather, promising a new wave of sustainable alternatives to environmentally destructive manufacturing practices. Leading innovators like Bolt Threads and Ginkgo Bioworks are creating new possibilities for industries reliant on petrochemicals. However, we must approach these developments with a critical eye. The term “bio-based” does not automatically equate to sustainability. The cultivation of feedstocks to produce these materials may compete with food production, and the scalability of these technologies remains an open question. Can synthetic biology truly provide solutions on the scale required to address global environmental challenges?
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Ethical and regulatory dilemmas
The transformative potential of synthetic biology comes with a hefty dose of risk. At its core, this field raises profound ethical issues. By altering organisms at the genetic level, we face the possibility of unintended consequences, such as gene flow to wild populations or the creation of new pathogens. The environmental impact of these genetic changes remains speculative, which necessitates cautious, measured advancement.
The regulatory landscape adds yet another layer of complexity. Governments are struggling to keep pace with the rapid progress of synthetic biology, creating a patchwork of regulations that may hinder innovation or, conversely, fail to protect public health and safety. Intellectual property rights are also murky, with patenting of genetic sequences leading to potential legal disputes and further complications.
Public opinion remains a wildcard. Despite the promise of synthetic biology, many consumers remain deeply sceptical of genetically modified organisms. A single public relations misstep could turn a promising technology into a pariah, demonstrating just how fragile public trust can be. Navigating this terrain will require more than technical expertise – it demands a commitment to transparent, open dialogue with the public.
A strategic investment approach
Given the complexity of synthetic biology, a cautious and strategic investment approach is essential. Investors must balance the enormous potential of this sector with its inherent risks. Diversification within synthetic biology may reduce some of these risks, but it could also dilute focus and hinder deep, specialised expertise. A rigorous approach to due diligence is vital, one that assesses not only the technological maturity of ventures but also their regulatory strategies and commitment to ethical principles.
Strategic partnerships between synthetic biology startups and established players may help expedite commercialisation, but they also risk stifling the very innovation that makes this field so compelling. The balance between fostering groundbreaking discoveries and ensuring safe, responsible growth will be delicate.
Synthetic biology stands at a critical juncture between innovation and ethical responsibility. Its potential is vast, but so are the risks and moral questions that accompany it. As investors, we must approach this space with both ambition and caution – recognising the immense opportunity while acknowledging the uncertainties and challenges that lie ahead. Those who engage critically with this rapidly evolving landscape may find substantial rewards. But blind faith in its promise could lead to costly mistakes and unforeseen consequences.
Rewriting life’s code is no small task. It requires not only vision but humility. As this field evolves, it is up to investors to navigate this delicate balance between ambition and caution, potential and responsibility. Only through thoughtful, ethical engagement can we hope to realise the true promise of synthetic biology.
The writer is head of Asia at CMC Markets Plc
Copyright SPH Media. All rights reserved.
